Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.

House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, Conzen SD, Ratain MJ.

Xenobiotica. 2017 Nov 10:1-11. doi: 10.1080/00498254.2017.1386335. [Epub ahead of print]

PMID:
29050522
2.

Perineural Invasion and Risk of Lethal Prostate Cancer.

Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):719-726. doi: 10.1158/1055-9965.EPI-16-0237. Epub 2017 Jan 6.

PMID:
28062398
3.

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.

Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ, Vander Griend DJ.

Oncotarget. 2016 May 3;7(18):26259-74. doi: 10.18632/oncotarget.8456.

4.

Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Reyes EE, Gillard M, Duggan R, Wroblewski K, Kregel S, Isikbay M, Kach J, Brechka H, Weele DJ, Szmulewitz RZ, Griend DJ.

J Transl Sci. 2015 Jul;1(1). pii: http://oatext.com/Molecular-analysis-of-CD133-positive-circulating-tumor-cells-from-patients-with-metastatic-castration-resistant-prostate-cancer.php. Epub 2015 Jul 30.

5.

Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.

Kibel AS, Ahn J, Isikbay M, Klim A, Wu WS, Hayes RB, Isaacs WB, Daw EW.

Prostate. 2016 Apr;76(5):479-90. doi: 10.1002/pros.23139. Epub 2015 Dec 28.

PMID:
26708993
6.

Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ.

J Transl Med. 2014 Nov 26;12:313. doi: 10.1186/s12967-014-0313-z.

7.

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ.

Horm Cancer. 2014 Apr;5(2):72-89. doi: 10.1007/s12672-014-0173-2. Epub 2014 Mar 11.

Supplemental Content

Loading ...
Support Center